Russia's Biocad To Build $40 Million Plant In Brazil To Supply Biosimilars
This article was originally published in PharmAsia News
Executive Summary
Russia's Biocad Pharmaceutical plans to open a $40 million facility in Brazil to produce at least three biosimilars by 2015.